Proactive Investors - Run By Investors For Investors

Imugene will present lead candidate HER-Vaxx at AACR Annual Meeting

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive Investors about the significance of presenting the clinical stage immuno-oncology company's lead candidate - the HER-Vaxx cancer vaccine - at the upcoming American Association for Cancer Research 2019 Annual Meeting.

HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

Meet White Rock Minerals Ltd and Meteoric Resources NL at our event, Melbourne , 27 August 2019. Register here »
View full IMU profile View Profile

Imugene Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use